Latest News

Ceapro Raises an Additional $310,000 through a Non-Brokered Private Placement

EDMONTON, ALBERTA – February 4, 2014 – Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that it has closed a $310,000 second tranche of its previously announced

Read more

Ceapro Raises $650,000 through a Non-Brokered Private Placement

EDMONTON, ALBERTA – January 21, 2014 – Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that it has received conditional TSX-V approval for and has closed a

Read more

Ceapro to Present at the Eighth Annual OneMedForum on Tuesday, January 13, 2015 – Presentation with Live Webcast scheduled for January 13, 2015, at 11:50 a.m. Pacific Time / 2:50 p.m. Eastern Time

EDMONTON, ALBERTA – January 8, 2015 – Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for health care and cosmetic industries, announced today that its President and Chief Executive Officer, Gilles Gagnon M.Sc., MBA,

Read more

Ceapro Announces Grant of Stock Options

EDMONTON, ALBERTA – January 7, 2015 – Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), today announced the granting of stock options to its employees, directors, and officers for a total of 950,000 stock options, each with an exercise price of $0.64. Each grant vests in three

Read more

Ceapro Enters into Financing Agreement with Agriculture Financial Services Corporation

EDMONTON, ALBERTA – December 18, 2014 – Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for health care and cosmetic industries, announced today that it has signed an Offer Letter with Agriculture Financial Services

Read more

Ceapro Awarded Research Grant from Alberta Innovates Bio Solutions to Develop Novel Formulations for Energy Drink – Grant supports collaboration with University of Alberta to advance Ceapro’s proprietary high-purity dry form Beta Glucan into an active ingredient in functional food

EDMONTON, ALBERTA – December 4, 2014 – Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for health care and cosmetic industries, announced today that it has been awarded a non-reimbursable grant of $198,000 by

Read more

Ceapro’s Research Scientist, Bernhard Seifried, Ph.D., Honored with Scientific Achievement & Innovation Award from BioAlberta – Ceapro’s PGX Technology enables production of pharmaceutical grade Beta Glucan

EDMONTON, ALBERTA – November 26, 2014 – Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that Bernhard Seifried, Ph.D., Senior Research Scientist at the Company, was recognized

Read more

Ceapro Appoints World Renowned Health and Disease Management Expert, William W. Li, M.D. to Board of Directors

EDMONTON, ALBERTA – November 20, 2014 – Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today the Company has appointed international health and disease management expert, William W.

Read more

Ceapro Inc. Reports Third Quarter 2014 Financial Results – Company delivers strongest quarterly financial performance in its history – Further increased revenue generation and market expansion expected in 2015

EDMONTON, ALBERTA – November 14, 2014 – Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today its financial results for the third quarter and nine-months ended September 30,

Read more

Ceapro Engages Jenene Thomas Communications, LLC as Strategic Investor Relations and Corporate Communications Advisor

EDMONTON, ALBERTA – November 13, 2014 – Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today the Company has engaged Jenene Thomas Communications, LLC to provide strategic investor

Read more
Page 5 of 10« First...34567...10...Last »